Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis
2
조회
0
다운로드
6
인용
0
참고문헌
초록
In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.
Abstract
In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H. pylori eradication, but no factors that can be predictive of the response to the eradication have been definitively identified, and there is little information on how to determine the optimal observation period before additional treatment can be started. Here, clinical studies dealing with the diagnosis and treatment of gastric MALT lymphomas and H. pylori published during the last 5 years were systematically reviewed, and studies identifying the molecular approaches involved in the pathogenesis were summarized. Most of the clinical studies indicate a favorable effect of H. pylori eradication on the clinical outcome of gastric MALT lymphomas. Some studies suggest the necessity of additional treatment in nonresponders to H. pylori eradication, while others suggest the adoption of a watch-and-wait strategy. The molecular characteristics of MALT lymphomas could play an important role in prognostic prediction and the selection of further therapeutic intervention after the eradication. This updated review of gastric MALT lymphomas illustrates the potential efficacy of H. pylori eradication in tumor remission, but further molecular characterization is necessary to establish the most suitable therapeutic strategy for patients who do not respond to eradication.
참고문헌 (38)
- Suzuki H, "Helicobacter pylori: present status and future prospects in Japan", J Gastroenterol, 42, pp.1~15 (2007)
- Stolte M, "Healing gastric MALT lymphomas by eradicating H. pylori?", Lancet, 342, pp.568~ (1993)
- Wotherspoon AC, "Regression of primary low-grade B-cell gastric lymphoma of mucosa- associated lymphoid tissue type after eradication of Helicobacter pylori", Lancet, 342, pp.575~577 (1993)
- Yi ZH, "Combined histology and molecular biology for diagnosis of early stage gastric MALT lymphoma", Chin J Dig Dis, 7, pp.12~18 (2006)
- Lo WY, "Instability of clonality in gastric lymphoid infiltrates: a study with emphasis on serial biopsies", Am J Surg Pathol, 29, pp.1582~1592 (2005)
- de Mascarel A, "Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue", Virchows Arch, 446, pp.219~224 (2005)
- Fujimori K, "Effect of Helicobacter pylori eradication on ongoing mutation of immunoglobulin genes in gastric MALT lymphoma", Br J Cancer, 92, pp.312~319 (2005)
- Todorovic M, "Primary gastric mucosa associated lymphoid tissue lymphoma: clinical data predicted treatment outcome", World J Gastroenterol, 14, pp.2388~2393 (2008)
- Nakamura T, "Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status", Am J Gastroenterol, 103, pp.62~70 (2008)
- Fischbach W, "Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series", Gut, 56, pp.1685~1687 (2007)
- Mee Joo, "Helicobacter heilmannii-associated Gastritis: Clinicopathologic Findings and Comparison with Helicobacter pylori-associated Gastritis", Journal of Korean Medical Science, 22(1), pp.63~69 (2007), 대한의학회
- Nakamura S, "Helicobacter pylori- negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment", Cancer, 107, pp.2770~2778 (2006)
- Hong SS, "A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication", Helicobacter, 11, pp.569~573 (2006)
- Wündisch T, "Long-term follow- up of gastric MALT lymphoma after Helicobacter pylori eradication", J Clin Oncol, 23, pp.8018~8024 (2005)
- Chen LT, "Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma", J Natl Cancer Inst, 97, pp.1345~1353 (2005)
- Fischbach W, "Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series", Gut, 53, pp.34~37 (2004)
- Kuo SH, "Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment", Ann Surg, 247, pp.265~269 (2008)
- Martinelli G, "Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy", J Clin Oncol, 23, pp.1979~1983 (2005)
- Radaszkiewicz T, "Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis", Gastroenterology, 102, pp.1628~1638 (1992)
- Mueller A, "Protective immunity against Helicobacter is characterized by a unique transcriptional signature", Proc Natl Acad Sci, 100, pp.12289~12294 (2003)
- Nakamura M, ""Candidatus Helicobacter heilmannii" from a cynomolgus monkey induces gastric mucosa-associated lymphoid tissue lymphomas in C57BL", 6 mice, 2007, pp.75, 1214~1222
- Liu H, "T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication", Gastroenterology, 122, pp.1286~1294 (2002)
- Nakagawa M, "Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein", Leukemia, 20, pp.929~936 (2006)
- Motegi M, "API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products", Am J Pathol, 156, pp.807~812 (2000)
- Hosokawa Y, "Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma", Cancer Res, 64, pp.3452~3457 (2004)
- Inagaki H, "Mucosa-associated lymphoid tissue lymphoma: molecular pathogenesis and clinicopathological significance", Pathol Int, 57, pp.474~484 (2007)
- Willis TG, "Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types", Cell, 96, pp.35~345 (1999)
- Zhang Q, "Inactivating mutations and overexpression of BCL10, a caspase recruitment domain- containing gene, in MALT lymphoma with t(1;14) (p22;q32)", Nat Genet, 22, pp.63~68 (1999)
- Lucas PC, "Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway", J Biol Chem, 276, pp.19012~19019 (2001)
- Liu H, "T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10", Blood, 98, pp.1182~1187 (2001)
- Huynh MQ, "Expression profiling reveals specific gene expression signatures in gastric MALT lymphomas", Leuk Lymphoma, 49, pp.974~983 (2008)
- Calin GA, "MicroRNA signatures in human cancers", Nat Rev Cancer, 6, pp.857~866 (2006)
- Lu J, "MicroRNA expression profiles classify human cancers", Nature, 435, pp.834~838 (2005)
- Suzuki H, "Overexpression of microRNA-142 and microRNA-155 in AP12-MALT1-positive gastric low-grade MALT lymphoma", Gastroenterology, 134, pp.A61~ (2008)
- Saito Y, "The role of microRNAs in gastrointestinal cancers", J Gastroenterol, 44(19), pp.18~22 (2009)
- Takino H, "p16", INK4a gene methyl ation is a frequent finding in pulmonary MALT lymphomas at diagnosis, 2005, pp.18, 1187~1192
- Min KO, "Methylation of p16 (INK4A) and p57(KIP2) are involved in the development and progression of gastric MALT lymphomas", Mod Pathol, 19, pp.141~148 (2006)
- Kaneko Y, "Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas", Gut, 52, pp.641~646 (2003)